PathWhiz

Pathway Description

Selexipag Action Pathway

Homo sapiens

Drug Action Pathway

Selexipag is a non-prostanoid prostacyclin receptor agonist, also known as Uptravi typically used to treat pulmonary arterial hypertension. Selexipag is a selective prostacyclin receptor agonist, it is administered orally and is metabolized by carboylesterase1 into its active metabolite (ACT-333679). The metabolite has a high selectivity for prostacyclin receptor that activates it and subsequent G coupled protein, Gs, that increases cAMP levels. Increased cAMP levels leads to inhibited platelet aggregation and activation.

References

Selexipag Pathway References

Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV: Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015 Dec 24;373(26):2522-33. doi: 10.1056/NEJMoa1503184.

Pubmed: 26699168

Chen M, Lai Y, Chen R, Lu J, Zhang Y, Liu H, Wang D, Zhong Y, Zheng Z, Hong C: Efficacy and safety of selexipag, an oral prostacyclin receptor agonist for the treatment of pulmonary hypertension: A meta-analysis. Pulm Pharmacol Ther. 2022 Feb;72:102100. doi: 10.1016/j.pupt.2021.102100. Epub 2021 Nov 29.

Pubmed: 34856365

Simonneau G, Torbicki A, Hoeper MM, Delcroix M, Karlocai K, Galie N, Degano B, Bonderman D, Kurzyna M, Efficace M, Giorgino R, Lang IM: Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012 Oct;40(4):874-80. doi: 10.1183/09031936.00137511. Epub 2012 Feb 23.

Pubmed: 22362844

Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.

Visualize Compound Data